Related Experiment Video
Updated: May 11, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Particle swarm optimization algorithm for analyzing SNP-SNP interaction of renin-angiotensin system genes against
Shyh-Jong Wu1, Li-Yeh Chuang, Yu-Da Lin
1Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan.
Abstract:
Most non-significant individual single nucleotide polymorphisms (SNPs) were undiscovered in hypertension association studies. Their possible SNP-SNP interactions were usually ignored and leaded to missing heritability. In present study, we proposed a particle swarm optimization (PSO) algorithm to analyze the SNP-SNP interaction associated with hypertension. Genotype dataset of eight SNPs of renin-angiotensin system genes for 130 non-hypertension and 313 hypertension subjects were included. Without SNP-SNP interaction, most individual SNPs were non-significant difference between the hypertension and non-hypertension groups. For SNP-SNP interaction, PSO can select the SNP combinations involving different SNP numbers, namely the best SNP barcodes, to show the maximum frequency difference between non-hypertension and hypertension groups. After computation, the best PSO-generated SNP barcodes were dominant in non-hypertension in terms of the occurrences of frequency differences between non-hypertension and hypertension groups. The OR values of the best SNP barcodes involving 2-8 SNPs were 0.705-0.334, suggesting that these SNP barcodes were protective against hypertension. In conclusion, this study demonstrated that non-significant SNPs may generate the joint effect in association study. Our proposed PSO algorithm is effective to identify the best protective SNP barcodes against hypertension.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Antihypertensive Drugs: Direct Renin Inhibitors
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Pharmacogenomics: Identification of New Drug Targets
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
